HTDK Honored as '2023 Most Innovative Enterprise' at VB100 Future Healthcare Awards

On May 6, 2023, at the 7th Future Healthcare 100 Conference, VCBeat released the “2023 Future Healthcare 100 List.” Huatang Dachang, leveraging itsDiversified Value-Added Commercial Services and the Expanding Incremental Market for Innovative Medical DevicesTwo major highlights earned the “2023 Future Healthcare Top 100 Pengcheng Award – Innovative Company of the Year.”

Launched in 2015, the Future Healthcare 100 ranking is China’s first list focused on innovative healthcare companies that are not publicly listed. It was introduced by VB100, VCBeat, and Eggshell Research Institute. The initiative aims to identify Chinese innovators who truly represent the future of healthcare, uncover the core driving forces behind China’s future healthcare industry, and promote innovation and transformation within the health and medical sector. Over the past seven years, the evaluation framework for the Future Healthcare 100 has been continuously enriched, gradually establishing a global innovation ecosystem in healthcare that serves enterprises, investment institutions, and industrial parks, while also expanding its scope to include innovative products and technologies.

After seven years of practice and exploration, the “Top 100 Future Healthcare Companies” list and awards have garnered strong support and recognition from numerous investment institutions and enterprises. It has become a bellwether for investment in the healthcare sector, guiding development and investment trends in China’s healthcare innovation field both currently and in the foreseeable future, while providing valuable reference for subsequent financing rounds by innovative companies.

Becoming an “invisible champion” in the medical device commercialization platform sector, Huatang Dachang is extending its service chain within its vertical niche by developing diversified value-added services beyond distribution, warehousing, and logistics. This marks a strategic shift from traditional horizontal expansion to vertical deepening, achieving end-to-end coverage along the service chain.

Over the past decade, the key to Huatang Dachang’s long-term, in-depth collaborations with global brands has been its end-to-end service platform. Unlike companies that offer only direct sales or distribution, Huatang Dachang provides comprehensive coverage of the entire process, including product registration, import and export, warehousing and distribution, channel management, inventory management, and after-sales management, delivering one-stop services for the commercialization of global brands in China. This has enabled brand partners to achieve rapid growth in the Chinese market by providing high-value-added services and solutions tailored to their specific industry or product characteristics and their respective stages of development.

In 2022, the partnership between Huatang Dachang and SOFWAVE MEDICAL LTD, an Israeli market-leading brand in the field of ultrasound-based anti-aging, expanded the company’s second growth engine. Huatang Dachang provides end-to-end professional commercial solutions for SOFWAVE MEDICAL LTD, facilitating both the registration and approval of its products with the National Medical Products Administration (NMPA) and accelerating comprehensive commercialization in the Chinese market, including product promotion, distribution, and sales.

Looking ahead, Huatang Dachang will continue to lead the industry through innovation, develop and advance its commercialization platform for high-value medical devices, enhance the accessibility of innovative global medical devices in China, address more unmet medical needs, and benefit a broad population of patients and the public.

Huatang DKSH is China’s leading cross-border commercial solutions platform, providing end-to-end professional commercial solutions for high-value medical devices. Its services cover product registration, import and export, warehousing and distribution, commercial channel management, inventory management, and after-sales management. Huatang DKSH traces its origins to the Chinese operations of DKSH, a Swiss company with a century-long history. In 1996, DKSH established its Shanghai branch in the Shanghai Waigaoqiao Free Trade Zone. In November 2018, Warburg Pincus, a global leading private equity investment firm, completed the 100% equity acquisition of DKSH’s Healthcare business in China. In January 2019, the independent company was officially renamed “Huatang DKSH.” After years of rapid development, Huatang DKSH has become a leading provider of commercial solutions in China, specializing in serving global brand owners of high-value medical devices. The company has accumulated extensive experience in serving global brands engaged in cross-border business. It has established long-term partnerships with numerous clients, covering high-value medical device brands across multiple medical specialties, including ophthalmology, in vitro diagnostics (IVD), orthopedics, cardiology, neurology, obstetrics and gynecology, vascular surgery, endocrinology, pulmonology, and high-value medical consumables. Our clients include globally leading brands such as Alcon, MicroVention, Illumina, Smith & Nephew, Roche, Abbott, and Procter & Gamble.